Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: histone and peptide based therapeutics - SymbioTec

Next Previous
Drug Profile

Research programme: histone and peptide based therapeutics - SymbioTec

Alternative Names: rhH1 x; rhH1.x

Latest Information Update: 25 Jan 2012

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SymbioTec
  • Class Peptides; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jan 2012 SymbioTec has been acquired by Xenetic Biosciences
  • 09 Jul 2010 No development reported - Preclinical for Cancer in Germany (unspecified route)
  • 24 Apr 2007 Preclinical trials in Acute myeloid leukaemia in Germany (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top